ARCUS BIOSCIENCES INC (RCUS:NYSE)
$17.89 -0.65 (-3.5059%)
Analysed ARCUS BIOSCIENCES INC (RCUS:NYSE) News Sources
Arcus stock tumbles 6% after unveiling casdatifan trial data
20-10-2026
yahoo.com
Arcus Reverses Course, Surging On Its Merck-Rivaling Cancer Reveal
20-10-2026
yahoo.com
Arcus Biosciences Sees $5B-$10B RCC Opportunity for Casdatifan at Investor Day
21-10-2026
marketbeat.com
Arcus kidney cancer data impresses analysts; TriGemX inks a SPAC deal
21-10-2026
biopharmadive.com
William Blair Expands Biotech Research as Veteran Analyst Alethia Young Initiates Coverage
21-10-2026
yahoo.com
Arcus Biosciences Announces Commencement of Public Offering of Common Stock
21-10-2026
yahoo.com
Arcus Biosciences stock falls on public offering announcement
21-10-2026
yahoo.com
Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock
22-10-2026
yahoo.com
Arcus Biosciences (RCUS) Stock Looks Stretched As Casdatifan Trial Data Impresses
24-10-2026
yahoo.com
How Investors May Respond To Arcus Biosciences (RCUS) $250 Million Share Sale
24-10-2026
yahoo.com
What is the current price of ARCUS BIOSCIENCES INC (RCUS:NYSE)?
The current price of ARCUS BIOSCIENCES INC (RCUS:NYSE) is $17.89.
ARCUS BIOSCIENCES INC (RCUS:NYSE) absolute price change since previous trading day?
The absolute price change of ARCUS BIOSCIENCES INC (RCUS:NYSE) since the previous trading day is $-0.65.
ARCUS BIOSCIENCES INC (RCUS:NYSE) percentage price change since previous trading day?
The percentage price change of ARCUS BIOSCIENCES INC (RCUS:NYSE) since the previous trading day is -3.5059%.
What is the most recent average sentiment score for ARCUS BIOSCIENCES INC (RCUS:NYSE)?
The most recent average sentiment score for ARCUS BIOSCIENCES INC (RCUS:NYSE) is 70 out of 100.
What is the most recent average sentiment for ARCUS BIOSCIENCES INC (RCUS:NYSE)?
The most recent sentiment for ARCUS BIOSCIENCES INC (RCUS:NYSE) is .
SEC-8K** Filing Available For ARCUS BIOSCIENCES INC (RCUS:NYSE)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.